<DOC>
	<DOCNO>NCT00431951</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics single , daily , oral dose ST-246 ( either 250 , 400 800mg ) administer 21 day 30 healthy , fed volunteer .</brief_summary>
	<brief_title>Phase I , Escalating , Multiple-Dose , ST-246 Safety , Tolerability Pharmacokinetics 21-Day Trial Healthy Volunteers</brief_title>
	<detailed_description>This double-blind , placebo-controlled , dose-escalating , multiple-dose study orally administer ST-246 30 healthy volunteer age 18-50 year , randomize receive either active drug ( 8 subject ) placebo ( 2 subject ) 1 3 dose group ( 250 , 400 800mg group ) . Each dose group 10 divide two cohort 5 subject ( 4 active 1 placebo ) . The first cohort dose approximately 4-8 week second cohort dose group . Dose group complete study treatment approximately 5 week prior start follow dose group . Study procedures include several overnight stay , medical history/exam , laboratory test do blood draw , electrocardiogram .</detailed_description>
	<criteria>Subject Healthy volunteer Ability Consent Not take medication Adequate venous access Using adequate birth control Subject Inability swallow study medication . Pregnant breastfeed Received experimental drug within 30 day study entry participate experimental study study period . Current drug abuse , alcohol abuse , homelessness . Taking concomitant medication Lactose Intolerance Medical condition ; e.g. , asthma , diabetes , thyroid disease , angioedema , BMI &gt; 35 &lt; 18 , hypertension , bleed disorder , malignancy , seizure , neutropenia , Hepatitis B C , HIV AIDS . Any condition , occupational reason responsibility , judgment Investigator , would jeopardize safety right volunteer , render subject unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>